About me
Professor Qinghua Wang has dedicated over 30 years to translational research in metabolic diseases. He began his medical training in Shanghai, followed by graduate studies in Biochemistry in Antwerp. By 2000, he became an Assistant Professor at the University of Toronto’s Department of Physiology — the same department where insulin was discovered a century ago. In 2014, he founded Innogen Pharmaceuticals and serves as its Founder, Chairman, and CEO. The company is a science-driven biopharmaceutical firm dedicated to developing innovative, accessible, and affordable medicines for metabolic diseases, including diabetes, obesity, and MASH. Innogen’s leading product, a humanized, long-acting GLP-1 RA, was approved for T2D in China in Jan 2025.
